Heron Therapeutics, Inc. (NASDAQ:HRTX) Holdings Raised by JPMorgan Chase & Co.

JPMorgan Chase & Co. increased its holdings in shares of Heron Therapeutics, Inc. (NASDAQ:HRTX - Free Report) by 295.8% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 206,711 shares of the biotechnology company's stock after acquiring an additional 154,487 shares during the quarter. JPMorgan Chase & Co. owned approximately 0.14% of Heron Therapeutics worth $411,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Principal Financial Group Inc. increased its stake in shares of Heron Therapeutics by 456.5% in the third quarter. Principal Financial Group Inc. now owns 102,651 shares of the biotechnology company's stock valued at $204,000 after purchasing an additional 84,205 shares during the period. Barclays PLC increased its stake in shares of Heron Therapeutics by 29.8% in the third quarter. Barclays PLC now owns 218,455 shares of the biotechnology company's stock valued at $434,000 after purchasing an additional 50,109 shares during the period. Y Intercept Hong Kong Ltd acquired a new stake in shares of Heron Therapeutics in the third quarter valued at approximately $39,000. XTX Topco Ltd increased its stake in shares of Heron Therapeutics by 449.0% during the third quarter. XTX Topco Ltd now owns 297,568 shares of the biotechnology company's stock valued at $592,000 after acquiring an additional 243,363 shares during the period. Finally, Zacks Investment Management increased its stake in shares of Heron Therapeutics by 2.4% during the third quarter. Zacks Investment Management now owns 475,575 shares of the biotechnology company's stock valued at $946,000 after acquiring an additional 11,320 shares during the period. Institutional investors and hedge funds own 80.01% of the company's stock.

Heron Therapeutics Stock Up 3.6 %

NASDAQ:HRTX traded up $0.06 during trading hours on Thursday, reaching $1.73. 1,042,464 shares of the company's stock were exchanged, compared to its average volume of 1,487,981. The company has a market capitalization of $263.13 million, a P/E ratio of -9.61 and a beta of 1.60. Heron Therapeutics, Inc. has a 12 month low of $1.04 and a 12 month high of $3.93. The business's 50-day simple moving average is $1.54 and its two-hundred day simple moving average is $1.88.

Heron Therapeutics (NASDAQ:HRTX - Get Free Report) last issued its earnings results on Tuesday, November 12th. The biotechnology company reported ($0.03) earnings per share for the quarter, hitting analysts' consensus estimates of ($0.03). The business had revenue of $32.81 million for the quarter, compared to the consensus estimate of $36.40 million. During the same quarter in the previous year, the business posted ($0.17) earnings per share. As a group, sell-side analysts anticipate that Heron Therapeutics, Inc. will post -0.13 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of research firms recently commented on HRTX. Needham & Company LLC reiterated a "buy" rating and set a $4.00 price objective on shares of Heron Therapeutics in a research note on Wednesday, December 4th. StockNews.com lowered shares of Heron Therapeutics from a "buy" rating to a "hold" rating in a research note on Wednesday.

About Heron Therapeutics

Heron Therapeutics, Inc, a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration.